Trial · NCT04569084
Adverse events150
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 150
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Edaravone 105 mg (Once Daily) | 24 | 192 | |
| other | Constipation | Gastrointestinal disorders | Edaravone 105mg (2 Weeks On/Off ) | 27 | 191 | |
| other | Diarrhoea | Gastrointestinal disorders | Edaravone 105 mg (Once Daily) | 20 | 192 | |
| other | Diarrhoea | Gastrointestinal disorders | Edaravone 105mg (2 Weeks On/Off ) | 14 | 191 | |
| other | Dysphagia | Gastrointestinal disorders | Edaravone 105 mg (Once Daily) | 11 | 192 | |
| other | Dysphagia | Gastrointestinal disorders | Edaravone 105mg (2 Weeks On/Off ) | 12 | 191 | |
| other | Fatigue | General disorders | Edaravone 105 mg (Once Daily) | 12 | 192 | |
| other | Fatigue | General disorders | Edaravone 105mg (2 Weeks On/Off ) | 10 | 191 | |
| other | Oedema peripheral | General disorders | Edaravone 105 mg (Once Daily) | 10 | 192 | |
| other | Oedema peripheral | General disorders | Edaravone 105mg (2 Weeks On/Off ) | 9 | 191 | |
| other | COVID-19 | Infections and infestations | Edaravone 105 mg (Once Daily) | 24 | 192 | |
| other | COVID-19 | Infections and infestations | Edaravone 105mg (2 Weeks On/Off ) | 26 | 191 | |
| other | Nasopharyngitis | Infections and infestations | Edaravone 105 mg (Once Daily) | 11 | 192 | |
| other | Nasopharyngitis | Infections and infestations | Edaravone 105mg (2 Weeks On/Off ) | 8 | 191 | |
| other | Contusion | Injury, poisoning and procedural complications | Edaravone 105 mg (Once Daily) | 17 | 192 | |
| other | Contusion | Injury, poisoning and procedural complications | Edaravone 105mg (2 Weeks On/Off ) | 14 | 191 | |
| other | Fall | Injury, poisoning and procedural complications | Edaravone 105 mg (Once Daily) | 36 | 192 | |
| other | Fall | Injury, poisoning and procedural complications | Edaravone 105mg (2 Weeks On/Off ) | 34 | 191 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Edaravone 105 mg (Once Daily) | 8 | 192 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Edaravone 105mg (2 Weeks On/Off ) | 20 | 191 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04569084/events